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 Tuberculosis (TB) treatment is a key pillar in the management and control of 
TB. Service delivery within the treatment facilities plays an important role in 
ensuring treatment adherence by TB patients. A prospective cohort study 
involving 25 health facilities, 25 facility in-charge officers and 291 patients 
diagnosed as new sputum smear positive (SM+) between December 2014 
and July 2015 was undertaken. The aim of the study was to estimate the 
median time to treatment interruption, associated factors and overall 
predictors of non-adherence to TB treatment. A total of 19 (6.5%) treatment 
interruptions were observed. The median time to default was 56 [95% CI, 36-
105] days. Treatment in a non-public facility [AOR=0.210, 95% CI (0.046-
0.952)] and facilities perceived to have adequate number of health care 
workers to offer Directly Observed Therapy (DOT) [AOR=0.195, 95% CI 
(0.068-0.56)] showed a lower odds of treatment interruption whereas 
attainment of secondary level education [AOR=5.28, 95% CI (1.18-23.59)] 
indicated a higher odds of treatment interruption. Non-clinical aspects of 
health care service delivery influence patient adherence to TB treatment. 
Health seeking behavior of groups considered to be high risk for treatment 
interruption should be incorporated into the design and delivery of TB 
treatment. 
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1. INTRODUCTION 
Tuberculosis (TB) is one of the infectious diseases of public health concern globally. According to 
WHO Global TB report (2016) there was an estimated 10.4 million new (incident) TB cases worldwide 
including 480,000 new cases of multidrug-resistant TB (MDR-TB) and an additional 100,000 people with 
rifampicin-resistant TB (RR-TB) [1]. Kenya is currently ranked among the top 20 countries with high TB, 
high TB/HIV and high MDR-TB burden, accounting for 84%, 87% and 84% of the global burden 
respectively. In 2015 the Kenya Division of Leprosy, Tuberculosis and Lung Disease (DLTLD) notified a 
total number of 81,518 of which 74,742 were new cases while 6,776 were previously treated cases. Nairobi 
County notified the highest number of cases at 12,385 [2].  
With correct management treatment success rates are high. If left untreated, TB has a high mortality 
rate. Poor adherence to anti-TB drugs can lead to emergence of drug resistant TB. Resistance to single drugs 
has been reported in every country and resistance to all of the major anti-tuberculosis drugs has now  
emerged [3]. Over the years, despite the decline in case finding for drug sensitive TB, Kenya has seen a 
gradual increase in DR-TB case notification from 112 cases in 2010 to 433 in 2015. Notably, there was a 
50% increase in 2015, compared to 288 cases in 2014.  
                ISSN: 2252-8806 
IJPHS Vol. 6, No. 3, September 2017 : 203 – 212 
204 
Availability of resources for TB care and prevention is one of the components in the implementation 
of WHO END TB strategy [4]. There is inadequate number of health care workers (HCWs) and skills across 
all cadres of human resources for health in Kenya. According to Kenya Service Availability and Readiness 
Assessment Mapping [5], the doctor-population ratio is less than one (<1) per 10,000 population. The nurse 
population-ratio was established as 3 per 10,000 people and for registered clinical officers 1 per 10,000. All 
other cadres of HCWs accounted for less than one (<1) per 10,000. This is very low compared to the WHO 
recommended standards of 23 doctors, nurses and midwives per 10,000 persons in a population. Significant 
workforce gaps are complicated by unequitable distribution of HCWs. The Health Sector-Human Resource 
Strategy (HS:HRS) 2014-2018 [6] projects that by the year 2030 there will be a challenge in filling general 
practitioner and nurses gaps in the country. Kenya has a total of 8,405 health facilities of which 49% are 
operated by the government (public). Of these 5,840 offer TB treatment services [5].   
The loss to follow up during tuberculosis (TB) treatment contributes to low treatment success rates 
and possible development of drug resistant TB (DR-TB). Kenya has seen an increase in cases of DR-TB case 
notification which is of great concern as is poses a threat to the gains made in reducing TB burden in the 
country. Successful treatment of drug sensitive TB is of utmost importance in ensuring that the chances of 
developing DR-TB are minimized. Adherence to the six month treatment regimen for all newly diagnosed 
patients cannot be overemphasized in the efforts to halt further increase in reported cases of MDR TB. In 
2015, Kenya recorded 4.3% treatment interruption rate amongst new pulmonary TB patients [2]. Factors that 
contribute to non-adherence should be addressed immediately to increase treatment success rates of drug 
susceptible TB and stop the surge in incidences DR-TB. Treatment interruption is defined as a patient being 
off- treatment for two consecutive months. 
 
 
2. METHOD 
2.1. Operational definitions 
Treatment interruption according, to the WHO and International Union against Tuberculosis and 
Lung Disease (IUATLD) guidelines is defined as TB patient who did not start treatment or whose treatment 
was interrupted for two consecutive months or more [7].  
Smear positive PTB was defined as a patient with at least one sputum smear examination positive 
for acid fast bacilli. Alternatively, patients whose two samples turned smear negative, were given antibiotics 
and on repeat diagnosis one sample turned positive for Mycobacterium tuberculosis bacilli, were also 
classified as SM+ [8]. 
 Treatment was administered according to the WHO/IUATLD guidelines [9]. The patients received 
a standardized Short-Course Chemotherapy (SCC) following the Directly Observed Therapy (DOTS) for 
treatment of TB strategy. The recommended regiment for treatment for new SM+ adults entailed two months 
of intensive phase treatment with four drugs consisting of Isoniazid (H), Rifampicin (R), Pyrazinamide (Z) 
and Ethambutol (E). This was then followed by a continuation phase of Rifampicin and Isoniazid (RH) for 
four months.  
 
2.2. Study site 
This study was conducted in Nairobi County which reports the highest CNR of SM+ PTB in the 
country [2]. A total of 25 facilities offering TB treatment within Nairobi County were included in the study. 
The facilities were selected based on the high number of TB patients receiving TB treatment. The sample size 
per facility was allocated proportionally based on the number of SM+ TB patients treated in 2013.  
 
2.3. Study design 
A prospective cohort study of patients diagnosed between December 2014 and July 2015 was 
undertaken. The patients were interviewed twice during the treatment period. The first interview was 
administered within the first three weeks of being diagnosed as SM+. The second interview was administered 
after 12 weeks of treatment. The facility in-charges were interviewed once within the study period. After six 
months of treatment, TB registers were reviewed to collect data on treatment outcomes.  
 
2.4. Study population 
The study participants constituted new SM+ PTB patients in Nairobi County. Only patients above 
15 years were included in the study for ease of sputum collection for confirmation as SM+ status. Patients 
who had been on treatment for more than three weeks were not included in the study. An informed consent 
was sought from each participant before data collection. Facility-in-charges from all participating facilities 
were included in the study. The hypothesis for the sample size calculation was based on an expected adverse 
treatment outcome of 12% in new smear positive TB cases and an absolute precision of 0.03. Furthermore 
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the sample size was increased by 20% for expected losses due to patients diagnosed as smear-positive who 
did not return for treatment. In total, 291(92% response rate) new SM+ TB patients and 25 (100% response 
rate) facility in charges were interviewed.  
 
2.5. Data collection  
Two data sources were used in the study. Structured Questionnaires were administered to the study 
participants within three weeks of starting treatment and once during the continuation phase to collect socio-
demographic and patient characteristics. Facility in-charge were interviewed to collect data on institutional 
characteristics. Treatment outcome(s) were extracted from the TB register at the end of the treatment period. 
The data collection tools were pretested to ensure that the questions were consistent. Data verification was 
carried out to ensure data validity. On receipt of questionnaires, internal and external consistency checks 
were carried out. A double entry procedure was adopted in data entry for all the data. The two image data 
files were compared for consistency. Discrepant values were checked against the original data file and values 
and inconsistencies were corrected. This led to the eventual creation of the final data base for safe keeping 
and analysis.  
 
2.6. Data analysis 
The computed descriptive statistics were used to describe data characteristics in terms of means and 
proportions. In bivariate analysis, Chi-square was used to test for association between the independent 
variables and treatment interruption. Kaplan-Meier failure estimates and log rank test were used to estimate 
average failure time, corresponding level of risk and difference in patient average time. Treatment 
interruption for reasons other than factor under analysis was censored in the Kaplan-Meier survival analysis. 
Cumulative risk of treatment interruption during the entire treatment period was determined. Cox regression 
hazard analysis was used to determine predictors of treatment interruption. Statistical significance was 
determined by considering nominal p-value of less than 5% (p< 0.05) with a 95% confidence level. Data was 
analyzed using Stata Corp. 2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP. 
 
 
3. RESULTS  
3.1. Socio demographic characteristics 
Of the 291 respondents, 215 (74%) were male. The TB patients had an average age of 32.3  
(22.3-42.3) years. Majority of the patients 147 (51.7%) had attained a secondary level of education, 99 (35%) 
primary level and 38 (13.3 %) post-secondary education. A large proportion of the study participants 212 
(74%) had a source of income of which 117 (55 %) were self-employed while 95 (45%) were employed by a 
third party. Persons employed by third parties were further segregated and clustered into groups based on the 
frequency of payment, 64 (64 %) received payment on a monthly basis, 16 (16%) on a weekly basis and 
19(19%) were paid on a daily basis. The patient socio-demographic characteristics were cross tabulated 
against TB treatment interruption shown in Table 1.  
 
 
Table 1. Cross Tabulation of Patient Socio-demographic Characteristics Against 
TB Treatment Interruption 
Socio-demographic characteristics 
TB Treatment Outcome 
No. Censored Treatment Interruption 
Gender Male 199(92.99%) 15(7.01%) 
 Female 71(95.95%) 3(4.05%) 
Age 15-24 47(88.68%) 6(11.32%) 
 25-34 127(93.38%) 9(6.62%) 
 35-44 59(93.65%) 4(6.35%) 
 45 plus 35(100%) 0(0.00%) 
Level of education Primary 95(96.94%) 3(3.06%) 
 Secondary 132(89.8%) 15(10.2%) 
 Post-Secondary  38(100%) 0(0.00%) 
Have Source of income Yes 196(92.89%) 15(7.11%) 
 No 71(94.67%) 4(5.33%) 
Type of source of income Self employed 110(94.02%) 7(5.98%) 
 Employed  86(91.46% 8(8.51%) 
Frequency of Wage payment Daily 16(84.21%) 3(15.79%) 
 Weekly 12 (80.00%) 3(20.00%) 
 Monthly 62(95.38%) 3(4.62%) 
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3.2. Patient characteristics 
At recruitment, 136 (46.7%) of the patients reported a history of smoking. The smokers were further 
clustered, based on the last time they smoked. The findings showed that majority of the patients, 75 (58.7%) 
had smoked within 8 weeks or less to the day of the interview. During the continuation phase, majority of the 
respondents 65 (88.9%), were not smoking. History of alcohol consumption was reported by 168 (58.3%) of 
the study participants on recruitment into the study. Majority had consumed alcohol within 8 weeks and less 
to the study point. During the continuation phase, most patients 85(89%) were not consuming alcohol. Most 
of the participants 253(94%) are spent one hour or less travelling to access a health facility. The mean travel 
time to the facility reported by the participants was 1.07 ± 0.3 hrs. From our findings, 87 (31%) of the 
participants suffered adverse reaction to TB treatment within the first three weeks of treatment. Skin irritation 
was the most common 33(37.9 %), side effect reported, During the continuation phase, the reported adverse 
reaction frequency among the study participants dropped to 49 (19%) of which skin irritation, 17(43%) was 
the most common. Within the first three weeks of treatment, relief on TB symptoms was reported by 157 
(72%) of the study participants, Most of them 75(51%), noted a reduction in coughing. The study participants 
reported presence of other chronic infections 51(18%) of which HIV/AIDS was the most common 36 (83. 
8%).  
 
3.3. Institutional characteristics 
A total of 25 facilities were included in the study. Public facilities accounted for 68% of the 
facilities while faith based and private institutions accounted for 24% and 8 % respectively. Majority of the 
facilities, 12 (48%) were level III (health centres), 10 (40%) level II (dispensaries) and 3 (12 %) level IV 
(district and sub district hospitals). Diagnostic and treatment services were offered in 21 (84%) of the 
facilities while 4 (16%) offered only treatment services. Among the institutions offering diagnosis, 20 
(95%) indicated that their lab staff had been trained specifically on TB diagnosis protocols. Availability of a 
specific TB clinic room was reported in 21 (84 %) of the facilities with 21 (80%) indicating that specific 
HCWs had been allocated to offer TB services. A further 21 (80%) facilities indicated that HCWs had been 
trained on TB management. Continuous counselling was offered to patients in 23 (96%) of these institutions 
throughout the treatment period while 19 (79%) reporting that they had enough HCWs to offer DOT 
support to patients. 
 
3.4. Socio demographic, patient and institutional characteristics association with treatment 
interruption 
Highest level of education reported by the participants showed statistically significant association 
with treatment interruption, χ2 (1, 243) =4.523, (p<0.033). Continued use of alcohol during treatment 
displayed a statistically significant association, χ2 (1, N=95) =5.732, (p<0.017). Amongst the institutional 
variables, statistically significant associations were observed between perceived availability of adequate 
HCWs to offer DOT support, χ2 (1, 275) =8.0005, (p<0.005 and nature of facility offering treatment, χ2 (1, 
92) =4.0350, (p<0.045). The other socio-demographic, patient and institutional variables did not exhibit 
statistically significant associations with treatment interruption. The socio-demographic, patient and 
institutional characteristics that that showed statistically significant association with TB treatment 
interruption are shown in Table 2.  
 
 
Table 2. Association Between Socio-demographic, Patient and Institutional Characteristics with 
TB Treatment Interruption 
Characteristics 
TB Treatment Outcome χ2 
(P-value) Number censored Treatment interruption 
Education level Primary 95(96.14%) 3(3.06%) 4.5(0.033) 
 Secondary 130(89.66) 14(10.34%) 
 
Alcohol on treatment Yes 8(72.73%) 3(27.27%) 5.7(0.017) 
 No 79(94.05%) 5(5.95%) 
 
Sufficient staff for DOT Yes 227(95.8%) 10 (4.2%) 8.0(0.005) 
 No 32(84.2%) 6(14.8%) 
 
Nature of facility Public 184(91.5%) 17(8.5%) 4.0(0.045) 
 Non-public 89(97.8%) 2(2.2%)   
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3.5. Survival analysis 
Out of the 291 patients, 19 (6.5%) interrupted their treatment. The median time to treatment 
interruption was 56 [95% CI, 36-105] days. Nine (47%) of the treatment interruptions occurred within the 
first two months of treatment. Kaplan-Meier failure estimate according to highest level of education (log rank 
test; P<0.018) and alcohol use during treatment (log rank test; P<0.017) displayed a significant difference 
shown in Figure 1. Of the institutional factors, perceived availability of adequate HCWs to offer DOT (log 
rank test; P<0.004) and nature of facility offering the treatment (log rank test; P<0.047), similarly displayed a 
statistically significant difference shown in Figure 2. 
 
 
  
 
Figure 1. Kaplan-Meier failure estimates for socio-demographic and patient characteristics that showed 
significant association with TB treatment interruption 
 
 
  
 
Figure 2. Kaplan-Meier failure estimates for institutional characteristics that showed significant association 
with TB treatment interruption 
 
 
3.6.    Risk of treatment interruption 
3.6.1. Socio-demographic, Patient Characteristics and Risk of Treatment Interruption 
During the entire treatment period, a 3.38 increase in risk for treatment interruption was observed 
amongst patients with secondary level education when compared to those with primary level education. 
Similarly, continued use of alcohol during treatment increased risk for treatment interruption by 4.04 fold 
compared to those who did not consume alcohol during treatment. The proportion of patients that interrupted 
TB treatment during the follow-up period clustered according to highest level of education and alcohol 
consumption during treatment is shown in Figure 3.  
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Figure 3. Proportion of treatment interruption during the follow-up period grouped according to highest level 
of education attained and alcohol consumption during TB treatment  
 
 
3.6.2. Institutional factors and risk for treatment interruption  
Facilities perceived to have inadequate staff to offer DOT support showed a 3.69 increase in risk for 
treatment interruption when compared to facilities that were perceive to have adequate staff. Additionally, 
public facilities had a 3.83 increase in risk for treatment interruption when compared to patients treated in 
private or faith based facilities. The proportion of patients that interrupted TB treatment during the follow-up 
period clustered according to perceived adequacy of HCWs in the treatment center and nature of the facility 
offering TB treatment is shown in Figure 4.  
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Figure 4. Proportion of treatment interruption during the follow-up grouped according to perceived adequacy 
of HCWs to offer DOT support and nature of facility offering TB treatment 
 
 
3.6.3. Cox proportional hazard 
Alcohol use during treatment, HR= 4.821 (95% CI 1.152-20.178) and perceived availability of 
adequate HCWs to offer DOT support HR = .253 (95% CI .092 - .697) showed significant association with 
treatment outcome on univariate analysis shown in Table 3. 
 
 
Table 3. Univariate Cox Proportional Hazard Analysis of Factors Associated 
with TB Treatment Interruption 
 Variable 
Univariate 
Hazard Ratio (95% CI) Z-Stat p>|z| Value 
Public vs. non-public .253 (.055-1.097) -1.84 0.066 
Adequate vs Inadequate HCWs  .253 (.092-.697) -2.66 0.008 
Primary vs Secondary  3.42  (.99-11.814) 1.94 0.052 
Alcohol use during treatment  4.82  (1.15-20.18) 2.15 0.031 
 
 
Nature of facility, adequacy of HCWs and highest level of education were included in the 
multivariate analysis. Alcohol use during treatment was excluded from the model due to low patients 
consuming alcohol during treatment. The three factors showed statistically significant associations with 
treatment default, χ2 (3,226) =17.37, (p<0.0006) shown in Table 4. 
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Table 4. Multivariate Cox Proportional Hazard Analysis of Factors Associated with TB  
Treatment Interruption 
 Variable 
Multivariate 
Adjusted Hazard Ratio  
Z-Stat p>|z| Value 
(95% CI) 
Public vs. non-public .210 (.046-.952) -2.02 0.043 
Adequate vs Inadequate HCWs  .195 (.068-.0.56) -3.03 0.002 
Primary vs Secondary  5.28 (1.18-23.59) 2.18 0.029 
 
 
4. DISCUSSION 
4.1. Treatment Interruption 
In this study 6.5% of the new SM+ TB patients interrupted their treatment. In Kenya, treatment 
interruption rates of 4.5% and 8.5% have been reported amongst new and retreatment TB patients’ 
respectively [10]. According to DLTLD 2015 report, the country’s treatment interruption rates were 4.3% 
and 3.4 % for the two groups’ respectively [2]. Other studies reported treatment interruption rates of 7.2 % 
among PTB patients in South Africa [11] and 8.9% in Ethiopia [12]. When all forms of TB are considered, 
reported treatment interruption rates included 11.1% [13] in Ethiopia, 7.4 % in India [14] and 11.5% in 
Kuwait [15]. There is a variation in treatment interruption rates between and within countries. These 
variations could be attributed to the status of TB control programs within the study regions in-country and 
between countries.  
 
4.2. Time to Treatment Interruption 
The median time to default was 56 days with majority of the patients defaulting during the transitory 
phase between intensive and continuation phase of treatment. The results were consistent with reported 
increase in hazard for treatment interruption during intensive phase in Kenya [10]. Similar results have been 
observed in India where up to 40% of default cases occurred during the same period [14]. In Kuwait 56% of 
treatment interruption were observed within the first two months of treatment [15]. In Moldova, the median 
time to default was 110 days and the highest risk was observed in the month immediately after intensive 
phase of treatment [16]. There is need to address individual and health system changes occurring during the 
transition phase of treatment in order to institute appropriate measures that would reduce loss to follow up 
during this period. These measures should be put in place immediately the patients begin TB treatment as the 
risk for interruption is highest within the first two months. 
  
4.3.    Risk Factors 
4.3.1. Highest Level of Education 
There was a significant association between highest level of education attained by the patients and 
TB treatment interruption. A 3.38 increase in risk for TB treatment interruption was observed amongst 
patients with secondary level education when compared to those with primary level education. The findings 
in this study therefore present a possible presence of a high risk group previously not considered. Further 
investigation into attitudes and health seeking behaviors in this category of patients need to be evaluated to 
understand the reason for increased risk in this group.  
 
4.3.2. Alcohol use During Treatment 
A statistically significant association was observed between continued alcohol use and treatment 
outcome. Patients who continued alcohol use during treatment had a 4.04 increase in risk for treatment 
interruption compared to those who did not consume alcohol. New cases with alcoholism and drug addiction 
have been shown to have an increased hazard of defaulting [16],[17]. In this study majority of study 
participants with a history of alcohol use, stopped alcohol consumption during TB treatment. Alcohol use 
impairs mental capability and this interferes with decision making capacity including adherence to TB 
treatment. There has been a call to action to address alcohol use and abuse to achieve optimal results in TB 
prevent and treatment [18]. Patients who continue use of alcohol during TB treatment should be considered 
high risk for treatment interruption.   
 
4.3.3. Availability of Adequate Health Care Workers 
Perceived inadequate availability of HCWs to offer DOT was identified as a risk factor for treatment 
interruption. There was a 3.69 f increase in risk for treatment interruption among patients treated in facilities 
that were perceived to have inadequate HCWs to offer DOT. A functional health system requires sufficient 
health workers, equitably distributed to improve coverage and accessibility. The need for adequate healthcare 
workers with the right skills cannot be overemphasized as a requirement to achieving health goals in a 
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population. There is limited literature published pertaining to HCW staffing levels and TB treatment 
outcomes. There is an urgent need to rigorously evaluate the importance of adequate staffing to provide 
evidence in designing optimal TB treatment guidelines. The results are supportive of the highlighted need for 
strategies to transform health workforce capabilities in order to achieve the target to end TB [19].  
 
4.3.4. Nature of Facility 
Tuberculosis treatment is offered in public and non-public facilities in Kenya. The nature of facility 
offering treatment showed a statistically significant association to treatment interruption. Patients who 
received treatment in public facilities had a 3.83 increase in risk for treatment interruption when compared to 
those who received treatment in non-public facilities. Similar results were reported in Nigeria where 
receiving treatment at a public facility was a predictor of unsuccessful treatment outcomes [20]. While there 
has been no evidence to show that there is better clinical services in non-public facilities, patients in private 
facilities reported better interpersonal satisfaction attributed to longer consultations times and higher chances 
of receiving counselling [21],[22]. In Kenya, public health facilities are known to be well stocked with TB 
tracer commodities to provide TB services [5]. There is need to determine whether patient interpersonal 
satisfaction over and above sufficient clinical services is a risk factor to TB treatment interruption.  
 
 
5. CONCLUSION 
Eliminating TB treatment interruption is a key factor in the fight against TB. Precautionary 
measures need to be put in place for patients who continue alcohol and drug use during TB treatment to 
prevent treatment interruption. Health system management changes occurring during the transition between 
intensive and continuation phase of treatment need to be evaluated to determine the reason for increased 
treatment interruption during that period of treatment. This study highlights the need to look at the human 
resource components in health facilities and the non-clinical institutional variables that are contributing to 
adverse treatment outcomes. Patient perception and attitude on quality and treatment approach, should to be 
integrated into all health facilities offering TB treatment.  
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